The multifaceted aspects of interstitial lung disease in rheumatoid arthritis by L. Cavagna et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 759760, 13 pages
http://dx.doi.org/10.1155/2013/759760
Review Article
The Multifaceted Aspects of Interstitial Lung
Disease in Rheumatoid Arthritis
Lorenzo Cavagna, Sara Monti, Vittorio Grosso, Nicola Boffini, Eva Scorletti,
Gloria Crepaldi, and Roberto Caporali
Division of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Viale Golgi 3, 27100 Pavia, Italy
Correspondence should be addressed to Lorenzo Cavagna; lorenzo.cavagna@unipv.it
Received 21 May 2013; Revised 15 August 2013; Accepted 20 August 2013
Academic Editor: Carlo Jose Freire de Oliveira
Copyright © 2013 Lorenzo Cavagna et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Interstitial lung disease (ILD) is a relevant extra-articular manifestation of rheumatoid arthritis (RA) that may occur either in early
stages or as a complication of long-standing disease. RA related ILD (RA-ILD) significantly influences the quoad vitam prognosis
of these patients. Several histopathological patterns of RA-ILD have been described: usual interstitial pneumonia (UIP) is the
most frequent one, followed by nonspecific interstitial pneumonia (NSIP); other patterns are less commonly observed. Several
factors have been associated with an increased risk of developing RA-ILD. The genetic background plays a fundamental but not
sufficient role; smoking is an independent predictor of ILD, and a correlation with the presence of rheumatoid factor and anti-cyclic
citrullinated peptide antibodies has also been reported.Moreover, both exnovo occurrence and progression of ILDhave been related
to drug therapies that are commonly prescribed in RA, such as methotrexate, leflunomide, anti-TNF alpha agents, and rituximab.
A greater understanding of the disease process is necessary in order to improve the therapeutic approach to ILD and RA itself and
to reduce the burden of this severe extra-articular manifestation.
1. Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory con-
dition that mainly affects joints, in terms of pain, erosion,
disability, and reduced survival [1–5]. RAmay be complicated
by several extra-articular manifestations (EAMs) [6–8]. The
lung is among the most important targets of EAMs; the spec-
trum of lung involvement in RA includesmanifestations such
as pleural disease, rheumatoid nodules, Caplan’s syndrome,
bronchiectasis [9, 10] and, in particular, interstitial lung
disease (ILD) [11–14].The first report of a correlation between
pulmonary fibrosis and RA was published in 1948 by Ellman
and Ball [11], describing three patients with polyarthritis and
interstitial pneumonitis with chronic fibrosing aspects on
autopsy. Since this first description as a “curious chronic
fibrosing bronchopneumonic lesion,” it has become clear
that RA associated interstitial lung disease (RA-ILD) actually
includes a broad spectrum of disorders that vary greatly in
their clinical presentation, pathology, and prognosis [9]. In
the following years several authors pointed out the relevance
of RA-ILD [15, 16], now widely accepted as an extra-articular
complication with deep impact on prognosis and on ther-
apeutic approach to RA [17–19]. Several histopathological
patterns of ILD have been described [17] and differential
diagnosis may be troublesome [20]. The etiopathogenesis
of RA-ILD is not completely understood although genetic
[21, 22], humoral [23], and environmental [24] factors seem
to be involved. The picture is further complicated by the
possible ILD-promoting effect of several drugs used to treat
RA such as DMARDs (e.g., methotrexate and leflunomide)
[25, 26] and biological agents (e.g., anti-TNF alpha and
rituximab) [27, 28]. In this review we evaluated the main
clinical characteristics of RA-ILD, the possible mechanisms
underlying the occurrence of this EAM, and the current
therapeutic approach.
2. Epidemiology and Prognosis
There is a great variation in the estimates of occurrence and
in the general aspects associated with RA-ILD; this is partly
due to the lack of acknowledged terminology and validated
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Table 1: Histologic and clinical classification of IIPs, applicable to RA-ILD (adapted from [29–31]).
Histologic patterns Clinical-radiological-pathologic diagnosis
Usual interstitial pneumonia (UIP) (Idiopathic) pulmonary fibrosis/(cryptogenic) fibrosing alveolitis (IPF/CFA)
Nonspecific interstitial pneumonia (NSIP) Nonspecific interstitial pneumonia (NSIP)
Organizing pneumonia (OP) Organizing pneumonia (preferred definition) = Bronchiolitis obliteransorganizing pneumonia (OP = BOOP)
Diffuse alveolar damage (DAD) Acute interstitial pneumonia (AIP)
Respiratory bronchiolitis (RB) Respiratory bronchiolitis interstitial lung disease (RB-ILD)
Desquamative interstitial pneumonia (DIP) Desquamative interstitial pneumonia (DIP)
Lymphoid interstitial pneumonia (LIP) Lymphoid interstitial pneumonia (LIP)
classification criteria, and to the different means of detection
employed to diagnose ILD. In 2002, the American Tho-
racic Society and European Respiratory Society (ATS/ERS)
redefined the nomenclature now used for acute and chronic
diffuse parenchymal lung diseases [29]. Because of the lack
of a dedicated classification, the consensus classification for
idiopathic interstitial pneumonias (IIPs) has been adopted
to define RA-ILD [30, 31]. RA-ILD can present as any of
the seven idiopathic interstitial pneumonias according to the
ATS/ERS consensus classification. Usual interstitial pneumo-
nia (UIP) and nonspecific interstitial pneumonia (NSIP) are
themain patterns of ILD described in RA although also other
forms, including lymphocytic interstitial pneumonia (LIP)
and organizing pneumonia (OP), have been less commonly
observed [14, 31, 32]. In Table 1 we summarized the different
patterns of ILD that may be detected in RA.
The predominance of UIP distinguishes RA from the
majority of other connective tissue diseases (CTDs), usu-
ally characterized by a prevalence of NSIP pattern [20,
33] although a bias related to diagnostic methodologies is
possible. Diagnostic accuracy of high resolution computed
tomography (HRCT) for UIP and NSIP with respect to
histological diagnosis has been reported to be approximately
70% in various studies, with possible discordance in up to
one-third of cases [34]. Despite these limits, the estimates of
RA-ILD prevalence likely fall in the range from 4% to 30%
[6, 14, 35], depending on detection methods and selection
criteria, and the incidence may be as high as 4.1 per 1,000
people with RA [17].
Although RA is predominant in females, RA-ILD is
frequently described in males [9, 10, 19, 31], with a 2 : 1 male
to female ratio [10]. It is interesting to observe that even if the
incidence of severe EAMs, such as vasculitis, has decreased
in the last decades, fewer changes have been observed for
ILD [36, 37]. ILD is frequently an early and asymptomatic
finding in RA; in a recent study up to 27% of patients had
HRCT findings of ILDwithin 2 years from disease onset [38],
whereas in another study 25% of RA patients had ILD already
diagnosed at presentation and another 25% developed ILD
within 3 years from disease onset [17].
RA-ILD is a significant cause of mortality, with a median
survival of 2.6 years versus 9.9 years of RA patients without
ILD. The standardized mortality ratio for RA-ILD compared
to RA alone is 2.86 [19]. The increased mortality in RA-ILD
is mainly due to ILD progression with respiratory failure and
direct RA complications [39]. Infectious processes, lung can-
cer, pulmonary embolisms, and other non-ILD pulmonary
conditions, although reported in the setting of RA-ILD [40],
are not so relevant on mortality rates as theoretically con-
ceivable [39]. The literature data show that ILD contributes
approximately to 6–13% of the excessmortality of RA patients
when compared to the general population [19, 39, 41], being
one of the most significant causes of death in these patients,
together with cardiovascular complications [7, 42].
Despite these data, ILD associated with collagen vascular
diseases, including RA, was reported to have a better progno-
sis than the idiopathic type of ILD [9, 31], even in cases of RA
patients with biopsy proven UIP [42]. A median survival of
60 months in RA-ILD compared with 27 months in IPF has
been reported [13]. However, this latter point is a matter of
debate; according to different authors the prognosis of RA-
UIP patients does not differ from that of IPF [11]. Possible
factors responsible for these contradictory results could be
the occurrence of subtle histologic differences not detectable
by conventional radiographic techniques but influencing the
correct diagnosis [34], the positive or detrimental influence
of immunosuppressive therapies used in the treatment of
RA, and the systemic consequences of a chronic autoimmune
disease such as RA. Differences in prognosis among RA-ILD
patients with different patterns of pulmonary involvement
have also been described. Several studies have suggested
a relationship of the UIP pattern to a shorter survival
particularly when compared to NSIP [10].
3. Risk Factors
Several environmental, serologic, clinical, and genetic factors
have been associated with the occurrence of RA-ILD. Occu-
pational exposure to inhaled pollutants such as silica may
lead to chronic lung inflammation and to the development of
various autoimmune diseases such as RA [43]. In established
RA, however, silica exposure is associated with the so called
“Caplan’s syndrome,” first described in the early fifties [44];
this is a peculiar syndrome characterized by the occurrence
of multiple well-defined rounded nodules on chest X-ray,
of various diameters, distributed throughout the lungs but
predominantly at the lung periphery [44, 45]. Lesions appear
often in crops may coalesce and form a larger confluent
nodule that often may cavitate or calcify [44, 45]. In subjects
not affected by RA, silica exposure is associated with a large
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amount of pathological lung conditions, such as pneumoco-
niosis, a peculiar form of interstitial lung disease that may
lead to progressive massive fibrosis; exposure to silica and
coal mine dusts may also result in pulmonary scarring in
a pattern that mimics idiopathic pulmonary fibrosis [46].
To date, the pathogenetic link between exposure to silica,
pneumoconiosis, Caplan’s syndrome, and RA has not been
clarified conclusively.
Smoking represents an independent risk factor for the
occurrence of both autoantibody-positive [47, 48] and
-negative RA [48]. The correlation is particularly evident
for heavy (≥10 pack-years) and currently smoking indi-
viduals [48, 49]. Smoking is associated with several lung
morbidities, including ILD [50–52]. The association with
smoking is particularly evident for the UIP pattern [30, 53–
55].However, in a recent study involving 356 RApatientswith
lung involvement (either ILD or airway disease), the strong
association between smoking history and ILD observed in
the univariate analysis was not confirmed in the multinomial
logistic regression analysis, thus suggesting that factors other
than smoking may trigger ILD occurrence in RA [23].
According to this study, possible risk factors for RA-ILD are
high titers of rheumatoid factor (RF), and to a lesser extent,
anticyclic citrullinated peptide antibodies (ACPA), carriage
of HLA-DRB1∗1502, and older age [23]. The association of
an increased risk of RA-ILD in RF positive patients has been
confirmed by other studies [38, 56]. Data regarding the effect
of ACPA on the development of lung disease are contradic-
tory, with some authors confirming the association [57, 58]
and others denying a possible role in the development of RA-
ILD [59]. It is interesting to observe that both RF and ACPA
can be present in smokers with ILD without clinical evidence
of RA [60, 61]. Furthermore citrullination processes have
been observed in lung tissue obtained fromRA-ILD [62], and
peculiar isoforms of citrullinated peptides, as, for example,
the Hsp90 Isoforms [63], may be important antigen targets in
RA-ILD.The increased citrullination of proteins and peptides
in the lung is potentially smoke related due to peptidylargi-
nine deiminase (PAD) increased activity and seems to play a
role not only in ILD but also in RA occurrence [64].The asso-
ciation with an allele connected with RA-ILD development,
but not with occurrence of RA itself, HLA-DRB1∗1502 has
been reported in a different study [65]. As recently described,
RA patients carrying DR2 serology (HLADRB1∗15 and 16
alleles) and DQB1∗06 have an increased risk of ILD, whereas
HLA-DRB1 Shared Epitope (SE) appears to be protective
against ILD development [66]. The protective role of HLA-
DRB1 SE is indeed an unexpected finding, being generally
associated with an increased risk of severe EAMs in RA
[67, 68]. It should be underlined that these results have been
observed in Japanese patients in whom theHLA allelic distri-
bution is quite different from that of other ethnicities; there-
fore, these associations [23, 65, 66] should be confirmed by
further studies. Older age has also been reported as a possible
risk factor for the development of ILD [17, 19, 23]. Koduri et al.
reported that risk estimates calculated on a 10-year difference
in age are associated with a 64% increase in the likelihood of
a RA patient of developing ILD over a shorter period of time
[17]. Similar results were obtained by Bongartz et al. [19] and
byMori et al. [23]. Although the reason for this association is
not completely clear, it is probably related to the established
evidence of an increased incidence of EAMs in older RA
patients (≥60 years) compared to younger ones [36, 69, 70].
Other risk factors associated with RA-ILD have been
reported: high RAdisease activity (e.g., DAS28 score) [19, 38],
high grade functional impairment (measured using health
assessment questionnaire) [17], and the presence of articular
erosions and rheumatoid nodules [19].
4. DMARDs and Biological Agents Related ILD
In clinical practice, one of the most controversial issues is the
possibility of ILD-promoting effects of someRA therapeutics.
In fact, drugs such as methotrexate (MTX), leflunomide
(LEF), antitumor necrosis factors (TNF) alpha agents, and
rituximab have been associated with ILD occurrence or
progression.
MTX may cause ILD/pneumonitis in 0.86%–6.9% of
patients with morbidity and mortality rates reaching 20%
[71]. As recently reported, this side effect may be triggered
by genetic factors; HLA-A∗31:01 allele has been reported to
be a possible predictor of MTX induced ILD in Japanese
patients [72]. This particular genetic subset is more common
in Japanese population compared to the Caucasian one (8.7%
versus 3.9%), possibly explaining the increased risk of this
drug side effect in Japan [73]. Even if environmental factors
may be involved [74], hypersensitivity is probably responsible
for most cases of pneumonitis associated with MTX, partic-
ularly in the case established lung disease [55, 75].
Leflunomide is also associated with ILD [76], with an
increased risk in the setting of preexisting lung disease and
a potential relevant impact on survival [77, 78]. Similarly
to MTX, hypersensitivity reactions may represent the main
mechanism of LEF-induced pneumonitis [79]. The develop-
ment of interstitial fibrosis is possibly connected with the
effect of A771726, an activemetabolite of LEF thatmay induce
the transition of lung epithelial cells to myofibrasts [80], a
phenomenon known as “epithelial-mesenchymal transition”
(EMT). EMT is usually involved not only in abnormal wound
repair and tissue remodelling, but also in organ fibrosis and
reasonably in ILD [81]. However, EMT is not the only patho-
genetic mechanisms in LEF-induced ILD. Experimental ani-
mal models demonstrated that the administration of LEF
alone did not induce the EMT phenotype, but when LEF was
administrated in the setting of a profibroting environment,
such as bleomycin-induced pulmonary fibrosis, EMT was
enhanced. This evidence suggests that the presence of other
fibrosis-inducing stimuli, like in the case of preexisting lung
fibrosis,may act as important risk factors for the development
of LEF-induced ILD [80].
In recent years an increased number of reports described
the new-onset or exacerbation of ILD after administration of
biologic therapies, in particular anti-TNF alpha agents [82–
84]. These drugs are pivotal in the treatment of several con-
ditions, in particular RA [85, 86]. ILDmay occur throughout
the entire course of therapy with these agents, with reports
ranging from few months to several years after treatment
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is introduced, with a mean interval of approximately 26
weeks. A possible correlation with RA-ILD has been reported
for all anti-TNF alpha agents approved for the treatment
of RA (infliximab, etanercept, adalimumab, certolizumab,
and golimumab) [83, 87, 88]. The mechanism of anti-TNF-
alpha induced ILD is not well established. TNF-alpha is
usually considered as a key cytokine in the pathogenesis
of interstitial pneumonia [89–91]. Paradoxically, anti-TNF
agents may actually have profibrotic effects on the lung. In
fact, TNF-alpha promotes apoptosis of pulmonary inflamma-
tory cells, thereby mediating tissue healing. Anti-TNF-alpha
therapies may inhibit these apoptotic processes and promote
persistence of inflammatory cells in the lung parenchyma
and eventually the development of ILD [92]. Support for
this hypothesis originates from experiments on TNF-alpha
homozygous knockout mice in which intratracheal admin-
istration of bleomycin resulted in an accelerated form of
pulmonary fibrosis. Exposing these mice to recombinant
TNF-alpha effectively reduced inflammation and promoted
lung tissue healing [93]. Anti-TNF therapy also promotes
the expression of antiinflammatory cytokines, such as TGF-
𝛽1, potentially contributing to profibrotic states [94]. Finally,
considering the role of TNF-alpha gene polymorphisms in
determing the effectiveness of anti-TNF alpha therapy [95,
96], it is tempting to speculate that a similar mechanismmay
be involved in the susceptibility to drug-induced ILD, but
further studies are needed to confirm this hypothesis.
Anti-TNF induced ILD may present with different pat-
terns of interstitial involvement, most commonly UIP or
NSIP; cases of organizing pneumonia, diffuse alveolar dam-
age, and lymphoid interstitial pneumonia have also been
described. Complete resolution may be observed in up to
40% after withdrawal of the biologic agent [83]. Mortality
can be as high as 30% of cases, rising to about 60% in case
of preexisting ILD [83]. Older age (>60–65 years) has been
reported as a negative prognostic factor [83, 88]. According
to data derived from one European biologics registry, general
mortality in RA-ILD does not seem to be different between
patients treated with conventional DMARDs or with anti-
TNF-alpha agents although the proportion of deaths directly
attributable to ILD is reported to be higher in this latter
group [97]. Further studies on higher numbers of patients are
required to confirm these results.
Despite the previously mentioned evidence, the associ-
ation of anti-TNF alpha treatment and ILD development
has been recently questioned. A large study including 8417
patients affected by RA, ankylosing spondylitis, psoriatic
arthritis, psoriasis, and inflammatory bowel disease did not
show an increased rate of ILD among the 4200 patients
treated with anti-TNF agents, compared to those treated
with non-biologic therapies, particularly in the RA group
(adjusted hazard ratio, 1.03; 95% CI 0.51–2.07) [98]. Reports
also suggest a possible improvement of RA-ILD following
treatment with infliximab [99–101] and etanercept [102, 103].
The peculiar and nonunivocal link between anti-TNF alpha
agents and ILD is clearly represented by a patient described
by Komiya et al.; in this case report the administration of
adalimumab first improved preexisting RA-ILD, and then
induced its progression [104].
Finally, also other biological therapies with different
mechanisms of action, including rituximab, have been
involved in the occurrence of ILD in RA patients [10]. Some
authors described the occurrence exnovo of ILD, following
rituximab infusion [28]. ILD has also been reported during
rituximab therapy for lymphoproliferative disorders [105].
The pathogenetic mechanism is not established. It is possible
that by targeting CD20 positive cells, rituximab induces B-
cell apoptosis, leading to antigen-presenting-cell maturation,
cytotoxic T-cell activation, and subsequent vascular and
alveolar damage [106]. In rituximab-ILD cytokine profile
shows an increase of proinflammatory molecules such as
IL-6 and TNF-alpha, with potential pathogenetic role in
promoting interstitial fibrosis [107].
5. RA-ILD: Potential Pathogenic Cascade
The pathogenesis of RA-ILD is far from being completely
clarified. Several multifactorial components and a large num-
ber of risk factors may be involved. Patients’ genetic asset
could be either predisposing (HLADRB1∗15, HLADRB1∗16,
DQB1∗06 [23, 66], and HLA-A∗31:01 [72] alleles, this latter
for MTX-related ILD) or protective (HLA-DRB1 SE [66]) for
the development of RA-ILD. Environmental factors play a
crucial role on a susceptible genetic background. Tobacco use
has been recognized as a possible trigger in the development
of RA-ILD. Smoking may directly injure respiratory epithelia
and vascular endothelial cells [108, 109] and stimulate protein
citrullination in the lung through local activation of PAD
enzymes [64]. Citrullinated proteins may be key elements
already at a preclinical level, acting as antigen targets for the
local immune response, eventually leading to ACPA forma-
tion, RAoccurrence [110], and finally lung interstitial involve-
ment, characterized by particularly enhanced citrullination
processes [23, 62, 63]. Furthermore, as previouslymentioned,
smoking may induce RF synthesis [111, 112] that has been
associated with an increased risk of RA-ILD by several
authors [19, 37, 41]. It is conceivable that smokingmay trigger
pulmonary immune response through direct lung damage,
enhancement of protein citrullination, and autoantibodies
synthesis (e.g., RF and ACPA). These events stimulate a local
inflammatory response characterized by cellular infiltration
and by the release of several mediators that further contribute
to tissue damage [14, 113]. It must be considered that smoking
is obviously not the only etiologic agent involved in the
development of the disease as demonstrated by the fact that
RA and RA-ILD often occur in nonsmokers. This suggests
that other environmental [114] or infectious [14] factors
are probably involved. Moreover, as analyzed in a previous
section, drug-induced ILD is another relevant issue.
Pulmonary cellular infiltrate in RA-ILD is heteroge-
neous, frequently organized in lymphoid nodular aggregates
[115], showing striking similarities with rheumatoid syn-
ovium [116]. Follicular B lymphocyte aggregates are mainly
peribronchiolar in disposition [117], resembling bronchial-
associated lymphoid tissue. These structures are involved in
antigen retrieval directly from lung lumen and not through
afferent lymphatics as in lymph nodes and are capable of
BioMed Research International 5
mounting adaptive immune responses [117]. Interestingly,
an increased number of peribronchiolar B-cell follicles have
been correlated with smoking [117], supporting once again
not only the possible role of the lung and of environmental
factors in promoting RA-ILD, but also RA itself [64, 117].
Follicular structures are generally accompanied by diffuse
infiltration of pulmonary interstitium by plasma cells that
may contribute to the humoral immune response through
the production of ACPA [117]. These antibodies complex
with citrullinated peptides through Fc receptors expressed on
antigen presenting cells, ultimately leading to the production
of proinflammatory cytokines, including TNF-alpha [64].
T-lymphocytes are essential to support B-cells activation
and differentiation following antigen exposure. An increased
CD4+ and, to a lesser extent, CD3+ T cells infiltrate has
been demonstrated in RA-ILD, particularly compared to IIP,
independently of the pattern of disease presentation (e.g., RA-
UIP or RA-NSIP) [118]. Other authors suggested that CD8+T
cells may also be important in the development of pulmonary
fibrosis in RA [119]. Although this hypothesis is supported by
a report showing that smoking increases the number of CD8+
T cells in lungs [120], this plausible mechanism of injury
should still be elucidated [119]. Furthermore, also neutrophils
may be relevant in RA-ILD as suggested by the correlation
of bronchoalveolar lavage neutrophilia and evidence of more
advanced interstitial fibrosis [119, 121]. The complexity of
lung cellular infiltrates has been confirmed in a recent model
of RA-ILD in SKG mice: infiltrating cells observed in this
model included CD4+ T cells, B cells, macrophages, and
neutrophils [122]. Cytokines and chemokines play a crucial
role in the interaction and crosstalk of the cellular network
in RA-ILD. TNF-alpha is a key proinflammatory cytokine in
the pathogenesis of interstitial lung involvement; it is mainly
produced by activated macrophages, lymphocytes, epithelial,
and endothelial cells. TNF-alpha plays a central role in
the stimulation of cell-cell adhesion and transendothelial
migration with a pivotal role in the early phases and in
the maintenance of cytokines and chemokines production
cascade [123]. TNF-alpha stimulates fibroblasts proliferation
promoting their ability to degrade the extracellular matrix
[124] and triggering the expression of growth factors such as
platelet derived growth factor-𝛽 (PDGF-𝛽) and transforming
growth factor-𝛽 (TGF-𝛽), cytokines such as interleukin-
4 (IL-4) and interleukin-13 (IL-13), and chemokines (e.g.,
CXCL5, CXCL8, CXCL12, and CXCL13) [14, 64, 125, 126]
that further contribute to stimulate fibroblast differentiation
and proliferation, thus potentially linking inflammatory and
fibrotic processes [127]. PDGF-𝛽 is produced by a wide array
of lung cells, including macrophages, fibroblasts, epithelial
and endothelial cells, [127, 128]. PDGF-𝛽 plays a primary
role in the pathogenesis of IPF, figuring among profibrotic
and proinflammatory molecules known to be critical in
the pathogenesis of ILD, such as TGF-beta and TNF-alpha
[127, 129]. It is interesting to note that the inhibition of
PDGF tyrosine kinase receptor significantly attenuates the
development of ILD in an experimental mouse model of
pulmonary fibrosis [130]. Further studies regarding the role
of PDGF in the development of RA-ILD are needed.
TGF-beta is produced by several cell types: macrophages,
epithelial, endothelial and dendritic cells, and fibroblasts
[127]. The profibrotic action of TGF-beta is mediated by
the recruitment and activation of monocytes and fibroblasts,
and by the induction of extracellular matrix deposition [127,
131]. TGF-beta also induces fibroblasts’ differentiation into
myofibroblasts, that represent the main source of extracel-
lular matrix in lung fibrogenetic processes [132]. The role
of chemokines (CXCL5, CXCL8, CXCL12, CXCL13) in the
recruitment and organization of lung interstitial inflamma-
tory infiltrate in RA-ILD is still largely unknown. These
chemokines are secreted by macrophages, fibroblast and
epithelial cells and act trough fibroblast recruitment and acti-
vation [127]. CXCL13 is a B-cells chemoattractant known to
regulate lymphoid follicules organization within rheumatoid
synovial tissue [116]. The exact role of this chemokine in the
lung parenchima still needs to be clarified although it has
been demonstrated that CXCL13 expression correlates with
the extent of inducible bronchus-associated lymphoid tissue
(iBALT) in patients with RA-ILD. This finding introduces a
possible fascinating connection of pathogenetic mechanisms
linking arthritis to extra-articular manifestations of RA.
Other mediators involved in this multi-step pathogenic
cascade include matrix metalloproteinases, originated from
damaged epithelia, that perpetuate this crosstalk between
inflammatory and fibrotic processes, by the enhancement
of cellular recruitment (B and T cells, macrophages, and
neutrophils) and by the production of additional profibrotic
mediators. Angiogenesis, induced by vascular endothelial cell
growth factor and by the proinflammatory milieu, is also
strictly connected with different phases of the pathological
processes of inflammation and fibrosis (Figure 1).
6. RA-ILD Diagnosis
Although some patients with proven RA-ILD can be asymp-
tomatic, the majority present with exertional dyspnoea and
dry cough. Pleuritic chest pain, fever, haemoptysis, and
tachypnoea are also common. Bibasal crackles on chest
examination are the most frequent finding [9, 31].
Plain chest radiography mainly reveals reticular and fine
nodular opacities. These findings are usually more concen-
trated in the lower lung zones. Chest radiography has a low
sensitivity for detection of ILD and can be normal in early
stages [9]. In the majority of patients pulmonary function
tests (PFT) demonstrate a restrictive defect with low forced
vital capacity (FVC), low total lung capacity (TLC) with
or without low diffusion capacity of the lung for carbon
monoxide (DLCO), and hypoxemia at rest or on exertion
[9, 31]. Decreased DLCO has been described in up to 40%
of RA patients without signs or symptoms of lung disease [9]
and is reported to be the most sensitive test for predicting the
presence of ILD on HRCT [133].
Bronchoalveolar lavage (BAL) is not routinely used as a
diagnostic modality in RA-ILD because BAL changes may
be seen even in the absence of ILD. BAL characteristics
in RA-ILD patients show a predominance of neutrophils
and macrophages [31]. The analysis of BAL fluid may not
be helpful to distinguish between different subtypes of
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Figure 1: Possible pathogenetic mechanisms involved in the occurrence of interstitial lung disease in rheumatoid arthritis. ILD: interstitial
lung disease, RF: rheumatoid factor, ACPA: anticyclic citrullinated peptide antibodies, VEGF: vascular endothelial growth factor, PDGF:
platelet derived growth factor, PAD: peptidylarginine deiminase, and MTX: methotrexate, MMP: metalloproteinase.
RA-ILD; however, a slightly higher percentage of neutrophils
(>4%) [134] may be more frequent in UIP. Lymphocytosis
(>18%) is more common in NSIP and OP [31]. Nevertheless,
the results of BAL cellularity may play a prognostic role,
with neutrophilia associated with more advanced disease
involvement and decreased response to therapy [134, 135].
BAL may also be useful in excluding infectious processes.
HRCT has been accepted as the standard noninvasive
method of diagnosing and following ILD in patients with
RA [136]. The results of HRCT have been shown to correlate
closely with those of open lung biopsy [13, 135]. The most
frequentHRCTfindings detected in different subtypes of RA-
ILD are presented in Table 2. High prevalence of enlarged
mediastinal lymphnodes in patients with ILD is described
[136].
Surgical lung biopsy provides the best means of estab-
lishing a histopathological diagnosis. However, because of the
potential risks associated with this procedure, many patients
are diagnosed without pathological confirmation. Usually,
video-assisted thoracoscopic surgery (VATS) is preferred to
open-lung biopsy. It is important to note that transbronchial
biopsies are not useful in the diagnosis, with the exception of
DAD/AIP, and occasionally organizing pneumonia OP/COP
[29]. Histological changes in RA-ILD are very similar to those
seen in IPF [9] and are summarized in Table 2.
The individuation of biomarkers to be used in the clinical
setting to guide diagnosis and response to treatment is still
ongoing. Increasing attention has been paid to a serologic
marker of pulmonary disease, KL-6 (Krebs von den Lungen-
6, a high molecular weight glycoprotein expressed on prolif-
erated type 2 alveolar pneumocytes and epithelial cells), that
is known to occur in patients with interstitial pneumonia,
hypersensitivity pneumonitis, tuberculosis, sarcoidosis, and
pulmonary alveolar proteinosis. It has also been reported that
KL-6 is elevated in RA-ILD [30, 137]. KL-6 can be used as a
useful marker reflecting the severity of pulmonary fibrosis,
the grade of alveolitis, and the extent of HRCT lesions and
for detecting active and progressive lung disease in RA-ILD;
however, KL-6 may not be very sensible in detecting early
stages of lung disease [137]. Oyama et al. [138] demonstrated
that KL-6 is elevated in 88.9% of patients with active ILD
and only in 0.6% of RA patients without active interstitial
disease. RA-ILD patients present high levels of proliferative
potential colony-forming cells (HPP-CFCs) in peripheral
blood compared to those without ILD [139]. High levels of
anti-cytokeratin 19 [140], IL-1, anti-IL1 antibodies, and serum
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Table 2: Histological and radiological patterns of RA-ILD [9, 10, 29–31].
Pattern Histology CT features CT differential diagnosis
UIP
Subpleural and peripheral fibrosis.
Fibroblastic foci, lymphoid aggregates
with germinal centres and honeycombing
are characteristic. Mild inflammation;
architectural destruction.
Peripheral, subpleural, basal reticulation,
and honeycombing
Traction bronchiectasis, architectural
distorsion, GGO (less diffuse). Subpleural
lines
IPF, other collagen vascular diseases,
hypersensitivity pneumonitis
(micronodules and sparing of lung
bases), sarcoidosis, asbestosis (pleural
thickening).
NSIP
Uniform interstitial involvement; various
degrees of fibrosis and/or inflammation.
Lymphoid aggregates. Rare
honeycombing
Bilateral, symmetrical, patchy, mainly basal
GGO, possible reticulation, traction
bronchiectasis, irregular lines, or
consolidation. Little or no honeycombing
(in fibrosing NSIP).
UIP, DIP, COP, hypersensitivity
pneumonitis, and HIV-associated
interstitial lung disease.
OP
Connective tissue plugs within small
airways and air spaces (Masson bodies).
Little or no inflammation or fibrosis.
Patchy and multiple airspace consolidation,
mainly basal, peripheral, or
peribronchovascular. Air bronchograms can
be seen. Possible associated GGO or
centrilobular nodules.
Infections, vasculitis, sarcoidosis,
alveolar carcinoma, lymphoma,
eosinophilic pneumonia, NSIP, and
COP.
DAD
(i) Acute phase: hyaline membranes,
edema.
(ii) Organizing phase: airspace and
interstitial organization
(i) Acute phase: progressive, patchy, or
diffuse GGO and dependent consolidation,
often with lobular sparing
(ii) Organizing phase: reticulation, traction
bronchiectasis, and architectural distorsion.
Hydrostatic edema, pneumonia,
eosinophilic pneumonia, and ARDS
(but more symmetrical and lower lung
zones)
DIP
Extensive macrophage accumulation in
the distal air spaces. Mild interstitial
involvement.
Patchy GGO, basal, and peripheral.
Microcystic changes within GGO, reticular
lines.
RB-ILD, hypersensitivity pneumonitis,
sarcoidosis, and Pneumocystis jiroveci
pneumonia.
RB-ILD Bronchiolocentric macrophageaccumulation. Mild bronchiolar fibrosis
Diffuse/upper lobes distribution,
centrilobular nodules, bronchial wall
thickening, and patchy GGO.
DIP, NSIP, and hypersensitivity
pneumonitis
LIP Bronchiolocentric lymphoid tissuehyperplasia
Diffuse, GGO, centrilobular nodules, septal
and bronchovascular thickening,
thin-walled cysts, and lymph node
enlargement.
Sarcoidosis, lympangitic carcinoma,
and Langherans’ cell histiocytosis
GGO: ground glass opacities; UIP: usual interstitial pneumonia, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia; COP: cryptogenic
organizing pneumonia; DAD: diffuse alveolar damage; DIP: desqumative interstitial pneumonia; RB-ILD: respiratory bronchiolitis-associated interstitial lung
disease; LIP: lymphoid interstitial pneumonia; IPF: idiopathic pulmonary fibrosis.
LDH are reported [141], but their clinical utility still has to be
better defined.
7. Differential Diagnosis
Differential diagnosis can be very challenging considering
that interstitial lung involvement is not exclusive of RA but
can be a complication of several conditions in the setting of
connective tissue diseases (CTD). Antisynthetase syndrome
(ASS) is the prototypical example of these conditions. ASS
is characterized by the occurrence of peripheral arthritis,
myositis, interstitial lung disease (ILD), typical cutaneous
manifestations (e.g., mechanic’s hands), and Raynaud’s phe-
nomenon, together with the positivity of antisynthetase
antibodies [20, 142]. In these patients, ILD is described in
up to 95% [20]. Arthritis is frequently symmetrical, and joint
erosions and ACPA positivity have been described also in
ASS patients [143], making the differential diagnosis between
RA and ASS particularly challenging. Some reports indicate
that the onset of different manifestations may be spread out
[144, 145] with patients presenting first with arthritis and then
with ILD. In our experience on 18 ASS, arthritis was the first
symptom in 5 cases; all patients developed ILD in a time
interval ranging from 3 months to 13 years.
Opportunistic infections, often connected with immuno-
suppressive treatments, particularly with biologic therapies,
can mimick RA-ILD and can represent a real diagnostic
challenge. Differential diagnosis in this setting can be even
more troublesome in the case of patients with preexisting ILD
[40]. Pathogens to consider as potential ILD mimickers are
Pneumocystis jiroveci, fungal [40] and viral infections such as
Epstein-Barr [146] and cytomegalovirus [147]. The main dif-
ferential diagnosis based on radiological aspects is presented
in Table 2. From the previously mentioned evidence it is clear
that differential diagnosis is fundamental in distinguishing
RA-ILD from different conditions that can be great mimick-
ers such as ASS or infectious diseases. This process is funda-
mental in order to promptly start the appropriate treatment,
with significant influence on patients’ prognosis [20, 148].
8. RA-ILD Treatment
To date, little is known about optimal treatment for RA-ILD
andwhether the pattern of ILDmay influence the response to
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immunosuppression [10]. For newly diagnosed patients, first-
line treatment is generally based on high dose corticosteroids
[149] that may be associated with immunosuppressants such
as cyclophosphamide [14, 150] and azathioprine [14, 151].
Mycophenolate mofetil should be considered as a potentially
useful treatment, considering its additional action on fibrob-
lasts, endothelial cells, and smooth muscle cells [151, 152].
Similarly to ASS [20, 148], good results have been obtained
with cyclosporine [153–156]. Despite the previously men-
tioned lung toxicity, cases of MTX and LEF efficacy in RA-
ILD have been reported [157]. As stated in a previous section,
the relationship between anti-TNF alpha agents and ILD is
far from being elucidated, and the role of rituximab has been
recently questioned after the first reports of drug-induced
ILD. Data are scarce regarding other biological therapies such
as abatacept or tocilizumab. This latter improved RA-ILD in
one single case report [158], whereas other authors addressed
ILD occurrence or exacerbation following tocilizumab ther-
apy [159, 160].
9. Conclusions
Although ILD is a well-established EAM of RA with a
substantial impact on prognosis, it is evident that several
aspects are far from being fully elucidated and are still
widely discussed. In particular, we should clarify the cascade
of events underlying the occurrence of ILD, by linking all
etiologic and pathogenetic steps, starting from established
risk factors (such as smoking) and resulting in the ultimate
pulmonarymanifestation (lung fibrosis).The comprehension
of these passages is mandatory in order to improve the
therapeutic approach of RA-ILD and to minimize the risk of
ILD development in potentially predisposed patients.
Glossary
ACPA: Anticyclic citrullinated peptide antibodies
AIP: Acute interstitial pneumonia
ASS: Antisynthetase syndrome
ATS/ERS: AmericanThoracic Society/European
Respiratory Society
BAL: Bronchoalveolar lavage
BOOP: Bronchiolitis obliterans organizing
pneumonia (recently classified as OP)
CFA: Cryptogenic fibrosing alveolitis
COP: Cryptogenic organizing pneumonia
CTDs: Connective tissue diseases
DAD: Diffuse alveolar damage
DIP: Desquamative interstitial pneumonia
DLCO: Diffusion capacity of the lung for carbon
monoxide
DMARDs: Disease modifying antirheumatic drugs
EAMs: Extra-articular manifestations
EMT: Epithelial-mesenchymal transition
FVC: Forced vital capacity
GGO: Ground glass opacities
HRCT: High resolution computed tomography
IIPs: Idiopathic interstitial pneumonias
IL-13: Interleukin-13
IL-4: Interleukin-4
IL-6: Interleukin-6
ILD: Interstitial lung disease
IPF: Idiopathic pulmonary fibrosis
KL-6: Krebs von den Lungen-6
LEF: Leflunomide
LIP: Lymphoid interstitial pneumonia
MMP: Metalloproteinase
MTX: Methotrexate
NSIP: NonSpecific Interstitial Pneumonia
OP: Organizing pneumonia (preferred
definition to BOOP)
PAD: Peptidylarginine deiminase
PDGF-𝛽: Platelet derived growth factor-𝛽
PFT: Pulmonary function tests
RA: Rheumatoid arthritis
RA-ILD: Interstitial lung disease in rheumatoid
arthritis
RB-ILD: Respiratory bronchiolitis interstitial lung
disease
RF: Rheumatoid factor
SE: Shared epitope
TGF-𝛽: Transforming growth factor-𝛽
TNF: Tumor necrosis factor
TLC: Total lung capacity
UIP: Usual Interstitial Pneumonia
VEGF: Vascular endothelial growth factor.
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